Health Fidelity, Prodigo, Werewolf Therapeutics, and Abound Bio were among the UPMC Enterprises’ portfolio companies in the news in the past month.
Vor Biopharma and Abound Bio have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments, with the goal of generating novel treatment systems for patients fighting acute myeloid leukemia (AML) and other devastating forms of blood cancer.
ALung Technologies Inc. is exiting the Covid-19 pandemic in a lot different shape than when it began, with a different pathway toward commercialization from what was originally planned.
Cavulus, a leading provider of Medicare Advantage member acquisition, enrollment management, and retention solutions, announced that its Medicare Advantage Platform has earned “Certified” status from HITRUST.
Health Fidelity Inc., a leading provider of innovative technologies for the value-based care era, announces that its Lumanent® Pre-Encounter Prep solution has been integrated with Epic and listed in the App Orchard.
Prodigo Solutions is pleased to welcome McLeod Health to its growing family of leading health systems using Prodigo’s supply chain platforms. McLeod recently chose Prodigo’s Marketplace and Data Hub platforms to replace its legacy supply chain technologies and to enhance its cloud-ERP migration strategy.
UPMC has launched Realyze Intelligence, a company that uses artificial intelligence and natural language processing to identify precise patient populations with chronic diseases and cancer to ensure they receive the most beneficial treatments.
Sempre Health has locked up another $15 million in financing as it looks to expand the company’s program to trim costs for behavioral health medication and cut skyrocketing health care system losses when patients skip their medications.
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing.
“Our recently completed IPO will help us advance our two lead programs to the clinic and will enable us to continue to build our immuno-oncology R&D organization,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
